Clinical Trial

Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies

Study acronym: SMART
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
To establish a prospective, multicenter, biopsie-confirmed clinical cohort of MAFLD-related cirrhosis (F3-F4) in China, and analyze the clinical, histopathological features and natural outcomes of MAFLD-associated liver fibrosis/cirrhosis in China. And than to conducted a real-world study of different strategies of Chinese characteristics for the prevention and treatment of MAFLD-related cirrhosis to evaluate the efficacy and safety of the strategies.
Trial Details
NCT Number NCT06135584
Lead Sponsor The Affiliated Hospital of Hangzhou Normal University
Conditions Metabolic Dysfunction-associated Fatty Liver Disease, Cirrhosis
Enrollment 1,000 participants
Start Date 2023-11-18
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-11-18